UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Acquires 6,401 Shares of Charles River Laboratories International, Inc. $CRL

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in Charles River Laboratories International, Inc. (NYSE:CRL) by 2.9% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 225,314 shares of the medical research company’s stock after acquiring an additional 6,401 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned 0.47% of Charles River Laboratories International worth $51,099,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also made changes to their positions in the company. Los Angeles Capital Management LLC acquired a new position in Charles River Laboratories International during the 4th quarter valued at about $42,000. Sfam LLC acquired a new stake in Charles River Laboratories International in the fourth quarter worth $43,000. Geneos Wealth Management Inc. raised its stake in Charles River Laboratories International by 98.0% during the 2nd quarter. Geneos Wealth Management Inc. now owns 293 shares of the medical research company’s stock worth $44,000 after buying an additional 145 shares during the period. Elyxium Wealth LLC bought a new position in shares of Charles River Laboratories International during the 4th quarter valued at about $46,000. Finally, Allworth Financial LP lifted its stake in Charles River Laboratories International by 61.3% in the fourth quarter. Allworth Financial LP now owns 350 shares of the medical research company’s stock valued at $70,000 after buying an additional 133 shares in the last quarter. Institutional investors and hedge funds own 98.91% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have recently commented on CRL. Sanford C. Bernstein set a $250.00 price target on Charles River Laboratories International in a report on Wednesday, July 1st. Barclays reaffirmed an “overweight” rating and set a $300.00 price target on shares of Charles River Laboratories International in a research report on Wednesday, August 5th. CLSA cut Charles River Laboratories International from an “outperform” rating to a “hold” rating and set a $219.00 price objective for the company. in a research report on Monday, July 20th. Mizuho set a $264.00 target price on shares of Charles River Laboratories International in a research note on Monday, August 10th. Finally, TD Cowen lifted their price target on Charles River Laboratories International from $235.00 to $300.00 and gave the stock a “buy” rating in a report on Monday, August 10th. Twelve equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $255.65.

Charles River Laboratories International Price Performance

Shares of CRL stock opened at $291.79 on Thursday. The company has a market cap of $13.93 billion, a P/E ratio of -60.16, a P/E/G ratio of 2.77 and a beta of 1.40. The company has a quick ratio of 1.04, a current ratio of 1.35 and a debt-to-equity ratio of 0.92. Charles River Laboratories International, Inc. has a twelve month low of $144.26 and a twelve month high of $303.30. The business has a fifty day simple moving average of $251.93 and a 200 day simple moving average of $199.91.

Charles River Laboratories International (NYSE:CRL) last posted its quarterly earnings results on Wednesday, August 5th. The medical research company reported $3.02 earnings per share for the quarter, beating analysts’ consensus estimates of $2.77 by $0.25. Charles River Laboratories International had a negative net margin of 5.96% and a positive return on equity of 15.75%. The company had revenue of $1 billion for the quarter, compared to the consensus estimate of $980.53 million. During the same period last year, the company posted $3.12 EPS. The firm’s quarterly revenue was down 2.7% compared to the same quarter last year. Charles River Laboratories International has set its FY 2026 guidance at 11.150-11.450 EPS. On average, sell-side analysts forecast that Charles River Laboratories International, Inc. will post 11.33 EPS for the current fiscal year.

Insider Activity

In other news, EVP Victoria L. Creamer sold 4,179 shares of Charles River Laboratories International stock in a transaction on Thursday, August 6th. The shares were sold at an average price of $259.16, for a total transaction of $1,083,029.64. Following the transaction, the executive vice president owned 30,051 shares in the company, valued at approximately $7,788,017.16. The trade was a 12.21% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Birgit Girshick sold 6,500 shares of Charles River Laboratories International stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $279.90, for a total value of $1,819,350.00. Following the transaction, the chief executive officer directly owned 36,013 shares in the company, valued at $10,080,038.70. The trade was a 15.29% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 165,990 shares of company stock valued at $42,606,388. 1.30% of the stock is currently owned by company insiders.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.